COMPASS MAGAZINE #11
COMPASS MAGAZINE #11
#2RESEARCH

DECIPHERING THE CODEGenomics makes progress, but raises privacy concerns

The cost of determining an individual’s genetic code with DNA sequencing has fallen sharply. As a result, testing individual patients for diseases caused by single-gene mutations has become common place, but genetic “cures” for complex and chronic diseases remain out of reach. To bridge the gap, projects around the globe are sequencing large groups of individuals in search of patterns – and raising significant ethical questions in the process.

#11EDITORIAL

EDITORIALMonica Menghini

Executive Vice President, Chief Strategy Officer

Dassault Systèmes

 
It is rare for a sequel to do better than the original. But that is precisely what is likely to happen in the case of platform business models.

The B2C platform model – the one that has made companies like Alibaba, Apple, Google and Amazon incredibly rich and influential – is the original story. It appeared in the 1990s. But now the sequel, the B2B platform business model, could end up stealing the show.

HAVE YOU HEARD?